D Dodick

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Headache as a symptom of ominous disease. What are the warning signals?
    D Dodick
    Mayo Clinic, Rochester, MN 55905, USA
    Postgrad Med 101:46-50, 55-6, 62-4. 1997
  2. ncbi request reprint A review of the clinical efficacy and tolerability of almotriptan in acute migraine
    David W Dodick
    Department of Neurology, Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Expert Opin Pharmacother 4:1157-63. 2003
  3. ncbi request reprint Migraine prevention
    D W Dodick
    Department of Neurology, Mayo Clinic Arizona, Scottsdale, Arizona 85259, USA
    Pract Neurol 7:383-93. 2007
  4. ncbi request reprint Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study
    David Dodick
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
    CNS Drugs 19:125-36. 2005
  5. ncbi request reprint Indomethacin-responsive headache syndromes
    David W Dodick
    Department of Neurology, Mayo Medical School, Mayo Clinic, 13400 East Shea Blvd, Scottsdale, AZ 85259, USA
    Curr Pain Headache Rep 8:19-26. 2004
  6. ncbi request reprint Triptans and chest symptoms: the role of pulmonary vasoconstriction
    D W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
    Cephalalgia 24:298-304. 2004
  7. doi request reprint Applying the benefits of the AwM study in the clinic
    D W Dodick
    Mayo Clinic, Scottsdale, AZ, USA
    Cephalalgia 28:42-9. 2008
  8. doi request reprint Pearls: headache
    David W Dodick
    Department of Neurology, Mayo Clinic Arizona, Phoenix, Arizona, USA
    Semin Neurol 30:74-81. 2010
  9. ncbi request reprint Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms
    D W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Cephalalgia 24:417-24. 2004
  10. ncbi request reprint Botulinum neurotoxin for the treatment of migraine and other primary headache disorders
    David Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Clin Dermatol 22:76-81. 2004

Detail Information

Publications90

  1. ncbi request reprint Headache as a symptom of ominous disease. What are the warning signals?
    D Dodick
    Mayo Clinic, Rochester, MN 55905, USA
    Postgrad Med 101:46-50, 55-6, 62-4. 1997
    ..These should prompt further investigation with MRI and/or lumbar puncture...
  2. ncbi request reprint A review of the clinical efficacy and tolerability of almotriptan in acute migraine
    David W Dodick
    Department of Neurology, Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Expert Opin Pharmacother 4:1157-63. 2003
    ..Drug-drug interaction studies indicate that almotriptan may be coadministered with other commonly prescribed drugs without dose modification. Almotriptan can be recommended as first-line treatment for acute migraine...
  3. ncbi request reprint Migraine prevention
    D W Dodick
    Department of Neurology, Mayo Clinic Arizona, Scottsdale, Arizona 85259, USA
    Pract Neurol 7:383-93. 2007
    ..Rational combinations of preventive medications may also be useful. This review provides an evidence and experience-based approach to the preventive treatment of migraine...
  4. ncbi request reprint Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study
    David Dodick
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
    CNS Drugs 19:125-36. 2005
    ..The objective of this study was to assess the efficacy, speed of onset and tolerability of the nasal spray formulation of zolmitriptan in migraine treatment...
  5. ncbi request reprint Indomethacin-responsive headache syndromes
    David W Dodick
    Department of Neurology, Mayo Medical School, Mayo Clinic, 13400 East Shea Blvd, Scottsdale, AZ 85259, USA
    Curr Pain Headache Rep 8:19-26. 2004
    ..Hypnic headache recently has been described as another primary headache disorder that may respond to indomethacin...
  6. ncbi request reprint Triptans and chest symptoms: the role of pulmonary vasoconstriction
    D W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
    Cephalalgia 24:298-304. 2004
    ..Pre-clinical studies of isolated pulmonary blood vessels may predict the clinical likelihood of chest symptoms; however, additional comparisons are needed...
  7. doi request reprint Applying the benefits of the AwM study in the clinic
    D W Dodick
    Mayo Clinic, Scottsdale, AZ, USA
    Cephalalgia 28:42-9. 2008
    ....
  8. doi request reprint Pearls: headache
    David W Dodick
    Department of Neurology, Mayo Clinic Arizona, Phoenix, Arizona, USA
    Semin Neurol 30:74-81. 2010
    ..Knowing some simple rules and standard questions will make the process almost fail proof...
  9. ncbi request reprint Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms
    D W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Cephalalgia 24:417-24. 2004
    ..If CNS side-effects are a clinically relevant concern in the individual patient, use of a triptan with a low incidence of CNS side-effects may offer the potential for earlier initiation of treatment and more effective outcomes...
  10. ncbi request reprint Botulinum neurotoxin for the treatment of migraine and other primary headache disorders
    David Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Clin Dermatol 22:76-81. 2004
    ..These studies may provide further evidence that BoNT/A is an effective option for the preventive treatment of migraine...
  11. ncbi request reprint Advances in migraine management: implications for managed care organizations
    David W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Manag Care 13:45-51. 2004
    ..The improved clinical profiles of the triptans provide substantial value to managed care organizations...
  12. ncbi request reprint Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project
    David W Dodick
    Department of Neurology, Mayo Clinic Scottsdale, AZ 85259, USA
    Curr Pain Headache Rep 8:435-42. 2004
    ..Using a multiattribute decision model, we combined these data on the importance of treatment attributes with information on the relative performance of the oral triptans derived from a recent meta-analysis of controlled clinical trials...
  13. doi request reprint Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan
    David W Dodick
    Department of Neurology, Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ 85054, USA
    Cephalalgia 31:296-300. 2011
    ..Sustained pain-free response with no adverse events has been recommended as a composite endpoint which measures the efficacy and tolerability attributes that patients desire...
  14. ncbi request reprint Clinical practice. Chronic daily headache
    David W Dodick
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Ariz 85259, USA
    N Engl J Med 354:158-65. 2006
  15. ncbi request reprint Recurrent short-lasting headache associated with paroxysmal hypertension: a clonidine-responsive syndrome
    D W Dodick
    Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Cephalalgia 20:509-14. 2000
    ..The pathophysiology of this syndrome and the mechanism of clonidine action are reviewed in the context of a possible failure of the baroreceptor reflex...
  16. ncbi request reprint Treatment and management of cluster headache
    D W Dodick
    Department of Neurology, Mayo Clinic, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA
    Curr Pain Headache Rep 5:83-91. 2001
    ..The cornerstone of maintenance prophylaxis is verapamil, yet methysergide, lithium, and divalproex sodium may also be employed. In some patients, melatonin or topiramate may be useful adjunctive therapies...
  17. pmc Thunderclap headache
    D W Dodick
    Department of Neurology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, Arizona 85259, USA
    J Neurol Neurosurg Psychiatry 72:6-11. 2002
    ..The clinical profile and differential diagnosis of thunderclap headache is described, and a nosological framework and diagnostic approach to this group of patients is proposed...
  18. ncbi request reprint Thunderclap headache
    David W Dodick
    Department of Neurology, Mayo Clinic, 13400 East Shea Blvd, Scottsdale, AZ 85259, USA
    Curr Pain Headache Rep 6:226-32. 2002
    ..This has created confusion regarding nosology and the nature and extent of the diagnostic evaluation, which this article discusses...
  19. ncbi request reprint Crossed cerebellar diaschisis during migraine with prolonged aura: a possible mechanism for cerebellar infarctions
    D W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
    Cephalalgia 28:83-6. 2008
    ..This case illustrates, for the first time, crossed cerebellar diaschisis in a patient with migraine with prolonged aura, and raises the possibility that hypoperfusion may be responsible in part for the development of these lesions...
  20. ncbi request reprint Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine
    David W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259, USA
    CNS Drugs 21:73-82. 2007
    ....
  21. doi request reprint Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs
    David W Dodick
    Mayo Clinic Hospital, Phoenix, Arizona 85054, USA
    Clin Ther 31:542-59. 2009
    ..The primary objective of this study was to compare the efficacy and tolerability of topiramate and amitriptyline in the prophylaxis of episodic migraine headache...
  22. ncbi request reprint Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study
    A M Rapoport
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Neurology 69:821-6. 2007
    ..To evaluate the efficacy and tolerability of zolmitriptan 5 mg and 10 mg nasal spray (ZNS) vs placebo in the acute treatment of cluster headache. Design/..
  23. ncbi request reprint Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet
    Egilius L H Spierings
    Brigham and Women s Hospital, Boston, Massachusetts 02481 2106, USA
    CNS Drugs 18:1133-41. 2004
    ..To determine the speed of onset of headache response and duration of response with zolmitriptan 5 mg orally disintegrating tablet (ODT) in the acute treatment of migraine...
  24. doi request reprint Refractory headaches due to multilevel thoracic cerebrospinal fluid leaks
    Terrence L Trentman
    Departments of Anesthesiology, Mayo Clinic Arizona, Phoenix, Arizona 85054, USA
    Pain Pract 8:394-8. 2008
    ..Spontaneous cerebrospinal fluid leak is a well-documented cause of postural headache. We report a medically refractory headache due to multilevel thoracic cerebrospinal fluid leaks...
  25. ncbi request reprint Migraine with aura is a risk factor for cardiovascular and cerebrovascular disease: a critically appraised topic
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
    Neurologist 13:231-3. 2007
    ..To determine whether migraine with aura and migraine without aura are independent risk factors for symptomatic cardiovascular and cerebrovascular disease...
  26. ncbi request reprint Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project)
    F Michael Cutrer
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Ther 26:1533-45. 2004
    ..Physicians treating patients with migraine can now choose from among 7 triptans, which differ on a range of attributes that may be important for treatment selection...
  27. ncbi request reprint Percutaneous occipital stimulator lead tip erosion: report of 2 cases
    Terrence L Trentman
    Department of Anesthesiology, Neurology, and Neurosurgery, Mayo Clinic, Scottsdale, AZ 85054, USA
    Pain Physician 11:253-6. 2008
    ..Lead erosion is a possible complication of occipital stimulation; strategies to reduce the risk of lead erosion are discussed, although further studies are needed to clarify the best surgical techniques...
  28. ncbi request reprint The impact of topiramate on health-related quality of life indicators in chronic migraine
    David W Dodick
    Mayo Clinic College of Medicine, Department of Neurology, Scottsdale, AZ, USA
    Headache 47:1398-408. 2007
    ....
  29. doi request reprint 2007 Scottsdale Headache Symposium
    Bert B Vargas
    Mayo Clinic, Department of Neurology, 5777 East Mayo Boulevard, Phoenix, AZ 85054, USA
    Expert Rev Neurother 8:201-4. 2008
    ....
  30. pmc Stroke telemedicine
    Bart M Demaerschalk
    Department of Neurology, Mayo Clinic Hospital, 5777 E Mayo Blvd, Phoenix, AZ 85054, USA
    Mayo Clin Proc 84:53-64. 2009
    ..The opportunities for future advances in telestroke practice, research, and education are considered...
  31. ncbi request reprint Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials
    David W Dodick
    Department of Neurology, Mayo Clinic Scottsdale, Ariz 85259, USA
    Headache 42:21-7. 2002
    ..Evaluate the effect of almotriptan on sustained pain-free outcome in patients with acute migraine...
  32. doi request reprint Cluster headache: diagnosis and treatment
    Rashmi Halker
    Department of Neurology, Mayo Clinic Arizona, Phoenix, Arizona, USA
    Semin Neurol 30:175-85. 2010
    ..As the sophistication of functional neuroimaging increases, better insight into the pathophysiological mechanisms that underlie cluster headache is expected...
  33. doi request reprint Responsiveness of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing to hypothalamic deep brain stimulation
    Mark K Lyons
    Department of Neurological Surgery, Mayo Clinic Arizona, Pheonix, Arizona 85054, USA
    J Neurosurg 110:279-81. 2009
    ..The authors report on a case of SUNCT syndrome successfully treated with hypothalamic deep brain stimulation and discuss the current literature...
  34. pmc Stroke team remote evaluation using a digital observation camera in Arizona: the initial mayo clinic experience trial
    Bart M Demaerschalk
    Cerebrovascular Diseases Center, Director, Stroke Telemedicine for Arizona Rural Residents, Division of Cerebrovascular Diseases, Division of Critical Care Neurology, Department of Neurology, Mayo Clinic Hospital, 5777 E Mayo Blvd, Phoenix, AZ 85054, USA
    Stroke 41:1251-8. 2010
    ....
  35. ncbi request reprint Migraine in special populations. Treatment strategies for children and adolescents, pregnant women, and the elderly
    Jonathan P Gladstone
    Department of Neurology, Mayo Clinic Scottsdale, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
    Postgrad Med 115:39-44, 47-50. 2004
    ..In this article, Drs Gladstone, Eross, and Dodick provide pearls for both abortive and prophylactic treatments for migraine in these populations...
  36. doi request reprint Occipital nerve stimulator placement under general anesthesia: initial experience with 5 cases and review of the literature
    Terrence L Trentman
    Department of Anesthesiology, Mayo Clinic, Phoenix, AZ 85054, USA
    J Neurosurg Anesthesiol 22:158-62. 2010
    ..Further studies are needed to correlate occipital nerve stimulator placement under general anesthesia and long-term headache control...
  37. ncbi request reprint Greater occipital nerve stimulation via the Bion microstimulator: implantation technique and stimulation parameters. Clinical trial: NCT00205894
    Terrence L Trentman
    Department of Anesthesiology, Mayo Clinic Arizona, Scottsdale, AZ 85054, USA
    Pain Physician 12:621-8. 2009
    ..Millions of patients suffer from medically refractory and disabling primary headache disorders. This problem has led to a search for new and innovative treatment modalities, including neuromodulation of the occipital nerves...
  38. ncbi request reprint Diagnosis and treatment of migraine
    Roger Cady
    Headache Care Center, Primary Care Network, Springfield, MO 65804, USA
    Mayo Clin Proc 77:255-61. 2002
    ..For prophylaxis, anticonvulsant drugs emerging as effective options are being added to the armamentarium with traditional compounds such as tricyclic antidepressants and beta-blockers...
  39. doi request reprint OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program
    David W Dodick
    Department of Neurology, Mayo Clinic Arizona, Phoenix, AZ, USA
    Headache 50:921-36. 2010
    ..To assess the efficacy, safety, and tolerability of onabotulinumtoxinA (BOTOX) as headache prophylaxis in adults with chronic migraine...
  40. ncbi request reprint Tearing without pain after trigeminal root section for cluster headache
    Helen Lin
    The Mayo Clinic, Scottsdale, AZ 85259, USA
    Neurology 65:1650-1. 2005
    ..These findings confirm that CH is generated by a central pacemaker and the pain may be expressed without activation of the peripheral trigeminovascular network...
  41. doi request reprint Predictors of migraine headache recurrence: a pooled analysis from the eletriptan database
    David W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Headache 48:184-93. 2008
    ....
  42. ncbi request reprint Clinical, anatomical, and physiologic relationship between sleep and headache
    David W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, Ariz 85259, USA
    Headache 43:282-92. 2003
    ..In patients with a well defined primary headache disorder, unless there are compelling historical or examination findings suggestive of a primary sleep disturbance, a formal sleep evaluation is seldom necessary...
  43. ncbi request reprint Hemicrania continua secondary to an ipsilateral brainstem lesion
    Marcelo M Valença
    Department of Neuropsychiatry, Federal University of Pernambuco, Recife, Brazil 50670 420
    Headache 47:438-41. 2007
    ..This case report shows anatomoclinical evidence of the involvement of brainstem structures on the pathophysiology of hemicrania continua...
  44. ncbi request reprint Cardiovascular tolerability and safety of triptans: a review of clinical data
    David W Dodick
    Department of Neurology, Mayo Clinic Scottsdale, AZ 85359, USA
    Headache 44:S20-30. 2004
    ..Therefore, the conclusions of this review cannot be extended to patients with cardiovascular disease. The cardiovascular safety profile of triptans favors their use in the absence of contraindications...
  45. ncbi request reprint Sumatriptan versus eletriptan: which is best?
    David W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
    Lancet Neurol 1:474. 2002
  46. ncbi request reprint Epidemiology and acute care of migraine headache
    David W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA
    Manag Care Interface 17:6-10; discussion 11-3. 2004
  47. ncbi request reprint Thunderclap headache
    David W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, Ariz 85259, USA
    Headache 42:309-15. 2002
  48. ncbi request reprint Thunderclap headache
    Todd J Schwedt
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Lancet Neurol 5:621-31. 2006
    ..Herein, we discuss the differential diagnosis of TCH, diagnostic criteria for the primary disorder, and proper assessment of patients. We also offer pathophysiological considerations for primary TCH...
  49. ncbi request reprint Diagnosis and treatment of cluster headache
    David J Capobianco
    Department of Neurology, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Semin Neurol 26:242-59. 2006
    ..As the sophistication of functional neuroimaging increases, so too will our ability to better understand the anatomic and metabolic perturbations that underlie cluster headache...
  50. ncbi request reprint SUNCT responsive to gabapentin
    Christopher H Hunt
    Department of Neurology, Mayo Clinic Rochester, Minn, USA
    Headache 42:525-6. 2002
  51. ncbi request reprint The young woman with postpartum "thunderclap" headache
    Jonathan P Gladstone
    Department of Neurology, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
    Headache 45:70-4. 2005
  52. ncbi request reprint Refining the clinical spectrum of chronic paroxysmal hemicrania: a review of 74 patients
    Christopher J Boes
    Department of Neurology, Mayo Clinic, Rochester 55905, MN, USA
    Headache 42:699-708. 2002
    ..To refine the clinical spectrum of chronic paroxysmal hemicrania (CPH)...
  53. ncbi request reprint Triptan nonresponder studies: implications for clinical practice
    David W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA
    Headache 45:156-62. 2005
    ....
  54. doi request reprint Triptan-induced latent sensitization: a possible basis for medication overuse headache
    Milena De Felice
    Department of Pharmacology, University of Arizona College of Medicine, Tucson, AZ, USA
    Ann Neurol 67:325-37. 2010
    ..Identification of the neural mechanisms underlying medication overuse headache resulting from triptans...
  55. ncbi request reprint Identifying migraine in primary care settings
    Richard Sadovsky
    Department of Family Practice, SUNY Downstate Medical Center, Brooklyn, New York 11203, USA
    Am J Med 118:11S-17S. 2005
    ..This will result in improved functionality and decreased pain, and may help prevent disease progression...
  56. ncbi request reprint A self-administered screener for migraine in primary care: The ID Migraine validation study
    R B Lipton
    Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Neurology 61:375-82. 2003
    ....
  57. doi request reprint CASE 1: the well-intentioned triptan prescriber
    David W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
    Headache 48:862-4. 2008
  58. doi request reprint Reflections and speculations on refractory migraine: why do some patients fail to improve with currently available therapies?
    David W Dodick
    Department of Neurology, Mayo Clinic Arizona, Phoenix, AZ, USA
    Headache 48:828-37. 2008
    ..This review considers current debate surrounding refractory migraine and poses the question, why do some patients fail to improve with currently available therapies?..
  59. ncbi request reprint Debate: analgesic overuse is a cause, not consequence, of chronic daily headache. Analgesic overuse is not a cause of chronic daily headache
    David W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, Ariz 85259, USA
    Headache 42:547-54. 2002
  60. ncbi request reprint Introduction: cardiovascular safety and triptans in the acute treatment of migraine
    David W Dodick
    Department of Neurology, Mayo Clinic Scottsdale, AZ 85259, USA
    Headache 44:S1-4. 2004
  61. ncbi request reprint Botulinum neurotoxin for the treatment of migraine and other primary headache disorders
    Andrew M Blumenfeld
    Department of Neurology, Kaiser Permanente, 4405 Vandever Avenue, San Diego, CA 92120, USA
    Dermatol Clin 22:167-75. 2004
    ..Educating patients and addressing headache triggers and optimizing acute treatment improve the outcome of any preventive program...
  62. ncbi request reprint Revised 2004 International Classification of Headache Disorders: new headache types
    Jonathan P Gladstone
    Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Can J Neurol Sci 31:304-14. 2004
    ..i-h-s.org) for the less commonly encountered or diagnostically challenging presentations of headache and facial pain...
  63. ncbi request reprint A not so uncommon cause of thunderclap headache
    David W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Headache 42:555. 2002
  64. ncbi request reprint Thunderclap stroke: embolic cerebellar infarcts presenting as thunderclap headache
    Todd J Schwedt
    Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Headache 46:520-2. 2006
    ....
  65. ncbi request reprint Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study
    David W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Headache 45:315-24. 2005
    ..Irvine, CA) for the prophylaxis of headaches in patients with chronic daily headache (CDH) without the confounding factor of concurrent prophylactic medications...
  66. doi request reprint Occipital nerve stimulation for headache: mechanisms and efficacy
    Peter J Goadsby
    Headache Group, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    Headache 48:313-8. 2008
    ..Other device-based therapies, such as deep brain stimulation for cluster headache and patent foramen ovale closure, are covered elsewhere...
  67. ncbi request reprint Duration of migraine is a predictor for response to botulinum toxin type A
    Eric J Eross
    Mayo Clinic College of Medicine, Mayo Clinic Scottsdale, AZ 85259, USA
    Headache 45:308-14. 2005
    ..To identify the clinical characteristics and/or injection parameters that predict a favorable response to botulinum toxin type A in patients with episodic and chronic migraine...
  68. ncbi request reprint Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial
    Stephen D Silberstein
    Jefferson Headache Center, Philadelphia, PA 19107, USA
    Headache 47:170-80. 2007
    ..To evaluate the efficacy and safety of topiramate (100 mg/day) compared with placebo for the treatment of chronic migraine...
  69. ncbi request reprint Is there a preferred triptan?
    David W Dodick
    Headache 42:1-7. 2002
  70. ncbi request reprint Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesis
    Andrew J Dowson
    King s Headache Service, King s College Hospital, London, UK
    CNS Drugs 19:483-97. 2005
    ..The quality of the clinical evidence on MOH is suboptimal and further biological and clinical research is urgently required to help facilitate the management of these patients more effectively in the future...
  71. ncbi request reprint How pain, including headache, becomes chronic
    David W Dodick
    Headache 47:1272-4. 2007
  72. ncbi request reprint Sinus headache: a neurology, otolaryngology, allergy, and primary care consensus on diagnosis and treatment
    Roger K Cady
    Headache Care Center, Primary Care Network, Inc, 3805 S Kansas Expressway, Springfield, MO 65807, USA
    Mayo Clin Proc 80:908-16. 2005
    ..However, this group agreed that greater diagnostic and therapeutic attention needs to be given to patients with sinus headaches...
  73. ncbi request reprint An otolaryngology, neurology, allergy, and primary care consensus on diagnosis and treatment of sinus headache
    Howard L Levine
    Cleveland Nasal Sinus and Sleep Center, Cleveland, Ohio, USA
    Otolaryngol Head Neck Surg 134:516-23. 2006
    ..However, there was a consensus from this group that greater diagnostic and therapeutic attention needs to be given to patients complaining of sinus headache that may indeed be due to the nose...
  74. ncbi request reprint Red ear syndrome
    R Allan Purdy
    Division of Neurology, Department of Medicine, Dalhousie University, QEII Health Sciences Center, Halifax, Nova Scotia, B3H 3Y9, Canada
    Curr Pain Headache Rep 11:313-6. 2007
    ..As a syndrome, it still lacks specificity in regard to etiology, mechanisms, and treatment but is important to recognize clinically because of its associations...
  75. ncbi request reprint Narrative review: reversible cerebral vasoconstriction syndromes
    Leonard H Calabrese
    Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Ann Intern Med 146:34-44. 2007
    ..In this review, we describe our current understanding of RCVS; summarize its key clinical, laboratory, and imaging features; and discuss strategies for diagnostic evaluation and treatment...
  76. doi request reprint Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial
    Richard B Lipton
    Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Lancet Neurol 9:373-80. 2010
    ..We aimed to assess the efficacy and safety of a new portable sTMS device for acute treatment of migraine with aura...
  77. ncbi request reprint CGRP antagonists in the acute treatment of migraine
    Richard B Lipton
    Department of Neurology, Epidemiology and Population Health, Albert Einstein College of Medicine, New York, NY, USA
    Lancet Neurol 3:332. 2004
  78. ncbi request reprint Painful ophthalmoplegia: overview with a focus on Tolosa-Hunt syndrome
    Jonathan P Gladstone
    Department of Neurology, Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Curr Pain Headache Rep 8:321-9. 2004
    ..Inflammatory conditions such as Tolosa-Hunt syndrome and orbital pseudotumor are highly responsive to corticosteroids, but should be diagnoses of exclusion...
  79. ncbi request reprint Caffeine for the prevention and treatment of postdural puncture headache: debunking the myth
    Rashmi B Halker
    Departments of Neurology, Division of Education Services, Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
    Neurologist 13:323-7. 2007
    ..Is caffeine effective in preventing and treating postdural puncture headache (PDPH)?..
  80. ncbi request reprint Facial pain
    Kenneth Hentschel
    Mayo Clinic College of Medicine, Mayo Graduate School of Medicine, Jacksonville, FL, USA
    Neurologist 11:244-9. 2005
    ..A thorough clinical history and physical examination may reveal the characteristic clinical features and assist in diagnosis. However, in some cases, the etiology may remain indeterminate...
  81. ncbi request reprint Migraine and cerebral white matter lesions: when to suspect cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
    Jonathan P Gladstone
    Mayo Clinic College of Medicine, Department of Neurology, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
    Neurologist 11:19-29. 2005
    ..The underlying pathogenesis of white matter lesions in migraineurs is unknown, and the lesions are usually nonspecific and of unclear clinical significance...
  82. ncbi request reprint Migraine with and without aura and risk for cardiovascular disease
    Bert B Vargas
    Department of Neurology, Mayo Clinic Hospital, 5777 East Mayo Boulevard, Phoenix, AZ 85054, USA
    Curr Atheroscler Rep 10:427-33. 2008
    ....
  83. ncbi request reprint Pathophysiology and management of transformed migraine and medication overuse headache
    Christopher J Boes
    Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Semin Neurol 26:232-41. 2006
    ....
  84. ncbi request reprint Prolonged neurologic complication and MRI abnormalities consequent to intracranial hypotension
    Eric J Eross
    Mayo Clinic Scottsdale, Scottsdale, Arizona, USA
    Headache 43:415. 2003
  85. doi request reprint Extracephalic cluster (cluster sine headache)
    Esma Dilli
    Mayo Clinic Arizona, 1340 East Shea Blvd, Scottsdale, AZ 85259, USA
    Neurology 70:1362-3. 2008
  86. ncbi request reprint Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside
    David W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Headache 43:S25-33. 2003
    ..These studies may provide further evidence that botulinum toxin type A is an effective option for the preventive treatment of migraine...
  87. ncbi request reprint Why migraines strike
    David W Dodick
    Mayo Clinic, Arizona, USA
    Sci Am 299:56-63. 2008
  88. ncbi request reprint Spontaneous CSF leak treated with percutaneous CT-guided fibrin glue
    Jonathan P Gladstone
    Division of Neurology, University of Toronto, Canada
    Neurology 64:1818-9. 2005
  89. doi request reprint Examining the essence of migraine--is it the blood vessel or the brain? A debate
    David W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
    Headache 48:661-7. 2008
    ..A debate is presented that examines whether it is the blood vessel or the brain that determines the essence of migraine...
  90. ncbi request reprint Migraine and white matter hyperintensities
    Alyx Porter
    University of Toronto, Division of Neurology, 1333 Sheppard Avenue East, Suite 122, M2J 1V1, Toronto, Ontario, Canada
    Curr Pain Headache Rep 9:289-93. 2005
    ..The ability to distinguish between nonspecific and disease-specific patterns of white matter hyperintensities in migraine sufferers is important for the practicing clinician...